OBJECTIVE: Supposing a "hyperdopaminergic State" associated at least with acute psychotic illness phases in schizophrenia, a direct relationship between striatal dopamine metabolism and the core psychopathological symptoms rarely can be provided. Recently, a new SPECT ligand to the presynaptic dopamine transporter (DAT) was introduced. Association of DAT availability and the acute psychotic syndrome is now demonstrated in a large cohort of first episode, never treated schizophrenic patients. METHODS: Twenty-eight inpatients suffering from a first acute exacerbation of schizophrenia and 12 healthy control subjects underwent SPECT scanning with the new radioligand [(99m)Tc]TRODAT-1. On the day of SPECT, psychopathology was assessed using specific scales including PANSS. RESULTS: There was no significant difference in [(99m)Tc]TRODAT-1 specific binding to the striatal DAT comparing both groups. The extend of hallucinations was significantly inversely correlated with DAT availability in patients with a predominantly positive syndrome type. DISCUSSION: Our data support evidence that differences in presynaptic dopaminergic activity in schizophrenic patients are associated with the extend of the acute psychotic syndrome. [(99m)Tc]TRODAT-1 seems to be a useful agent for in vivo assessment of a psychopathological association with dopamine metabolism.
OBJECTIVE: Supposing a "hyperdopaminergic State" associated at least with acute psychotic illness phases in schizophrenia, a direct relationship between striatal dopamine metabolism and the core psychopathological symptoms rarely can be provided. Recently, a new SPECT ligand to the presynaptic dopamine transporter (DAT) was introduced. Association of DAT availability and the acute psychotic syndrome is now demonstrated in a large cohort of first episode, never treated schizophrenicpatients. METHODS: Twenty-eight inpatients suffering from a first acute exacerbation of schizophrenia and 12 healthy control subjects underwent SPECT scanning with the new radioligand [(99m)Tc]TRODAT-1. On the day of SPECT, psychopathology was assessed using specific scales including PANSS. RESULTS: There was no significant difference in [(99m)Tc]TRODAT-1 specific binding to the striatal DAT comparing both groups. The extend of hallucinations was significantly inversely correlated with DAT availability in patients with a predominantly positive syndrome type. DISCUSSION: Our data support evidence that differences in presynaptic dopaminergic activity in schizophrenicpatients are associated with the extend of the acute psychotic syndrome. [(99m)Tc]TRODAT-1 seems to be a useful agent for in vivo assessment of a psychopathological association with dopamine metabolism.
Authors: M Laruelle; A Abi-Dargham; C van Dyck; R Gil; D C D'Souza; J Krystal; J Seibyl; R Baldwin; R Innis Journal: Biol Psychiatry Date: 2000-03-01 Impact factor: 13.382
Authors: S K Meegalla; K Plössl; M P Kung; D A Stevenson; M Mu; S Kushner; L M Liable-Sands; A L Rheingold; H F Kung Journal: J Med Chem Date: 1998-02-12 Impact factor: 7.446
Authors: A Breier; T P Su; R Saunders; R E Carson; B S Kolachana; A de Bartolomeis; D R Weinberger; N Weisenfeld; A K Malhotra; W C Eckelman; D Pickar Journal: Proc Natl Acad Sci U S A Date: 1997-03-18 Impact factor: 11.205
Authors: J Hietala; E Syvälahti; K Vuorio; V Räkköläinen; J Bergman; M Haaparanta; O Solin; M Kuoppamäki; O Kirvelä; U Ruotsalainen Journal: Lancet Date: 1995-10-28 Impact factor: 79.321
Authors: J Lavalaye; D H Linszen; J Booij; P M Dingemans; L Reneman; J B Habraken; B P Gersons; E A van Royen Journal: Schizophr Res Date: 2001-01-15 Impact factor: 4.939
Authors: David L Copolov; Marc L Seal; Paul Maruff; Recep Ulusoy; Michael T H Wong; Henri J Tochon-Danguy; Gary F Egan Journal: Psychiatry Res Date: 2003-04-01 Impact factor: 3.222
Authors: Klaus Henning Krause; Stefan H Dresel; Johanna Krause; Christian la Fougere; Manfred Ackenheil Journal: Neurosci Biobehav Rev Date: 2003-11 Impact factor: 8.989
Authors: Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky Journal: Pharmacol Rev Date: 2008-09 Impact factor: 25.468
Authors: Jose J Mateos; Francisco Lomeña; Eduard Parellada; Font Mireia; Emili Fernandez-Egea; Javier Pavia; Alberto Prats; Francisca Pons; Miquel Bernardo Journal: Psychopharmacology (Berl) Date: 2006-09-22 Impact factor: 4.530
Authors: G J E Schmitt; S Dresel; T Frodl; C la Fougère; R Boerner; K Hahn; H-J Möller; E M Meisenzahl Journal: Eur Arch Psychiatry Clin Neurosci Date: 2011-11-13 Impact factor: 5.270
Authors: Zhihua Xie; Eric J Vallender; Naichen Yu; Shelli L Kirstein; Hong Yang; Mary E Bahn; Susan V Westmoreland; Gregory M Miller Journal: J Neurosci Res Date: 2008-11-15 Impact factor: 4.164